欢迎访问《岭南现代临床外科》官方网站,今天是

岭南现代临床外科 ›› 2015, Vol. 15 ›› Issue (04): 513-516.DOI: 10.3969/j.issn.1009-976X.2015.03.040

• 综述 • 上一篇    下一篇

RKIP在肿瘤中的研究进展

杨克戈1,黄开红2   

  1. 1. 中山大学孙逸仙纪念医院
    2. 中山大学附属孙逸仙纪念医院
  • 通讯作者: 黄开红

The research advances of Raf kinase inhibitory protein (RKIP) in cancer

  • Received:2015-03-16 Revised:2015-04-13 Online:2015-08-20 Published:2015-08-20

摘要: 【摘要】〓RKIP(Raf kinase inhibitory protein)作为脂酰乙醇胺结合蛋白家族中的一员,最初时是在牛的大脑中被发现,后来被证实能够抑制MAPK通路的激活,同时RKIP又参与了NF-κB和G蛋白偶联受体信号通路的调控。RKIP与肿瘤的转移能力和治疗敏感性密切相关,RKIP缺失会导致肿瘤转移能力与耐药性增强,但具体机制仍不清楚。通过结合临床资料,RKIP可能是一种评估肿瘤预后的新的生物学标志物。随着RKIP与肿瘤的研究不断深入,它将有可能成为肿瘤的治疗新的靶点,本文就RKIP在肿瘤中的研究状况进行简要综述。

关键词: RKIP, 转移, 耐药, 预后因子

Abstract: 【Abstract】〓Raf kinase inhibitory protein (RKIP) was initially identified as phosphatidylethanolamine binding protein in bovine brain. Later RKIP has emerged as a critical molecule for regulating activation of MAPK, NF-κB and G protein coupled receptors (GPCRs). The disruption of RKIP in a wide range of pathologies, including cancer metastasis and therapeutic resistance makes it an exciting target for individualized therapy and disease-specific interventions. By combing clinical data analysis, RKIP became a new biological marker that reflects the prognosis of tumor. This review attempts to highlight recent advances in the RKIP field underscoring its potential role as a master modulator of many pivotal intracellular signaling cascades that control cancer metastasis and therapeutic resistance, and as a prognostic factor of tumor.

Key words: RKIP, Metastasis, Therapeutic resistance, Prognostic factor

中图分类号: